The Premium Business Information Source™
Report title:
ASTRAZENACA PORTFOLIO & PIPELINE ANALYSIS
from
TF Market Research
91 page report published Mar 15, 2001
Price
$3,600.00
available for immediate download
This report is also available for purchase on a
per-page basis
.
Report Overview
Purchase by Section
About TF Market Research
Source:
DATAMONITOR
Company:
ASTRAZENECA
Geographic Regions:
EUROPE, UNITED KINGDOM/GREAT BRITAIN/BRITISH ISLES, WESTERN EUROPE REGION
Industries:
BIOTECHNOLOGY, MEDICAL SUPPLY, PHARMACEUTICALS
Products:
ANTIASTHMA DRUGS, ANTICANCER AGENTS, DRUGS, RESPIRATORY CARE DEVICES
Subjects:
ANNUAL/OPERATING RESULTS, COMPANY ANALYSES, COMPANY DESCRIPTION, CORPORATE STRUCTURE, CORPORATE STRATEGY, MARKET SIZE/DEMOGRAPHICS, GOVERNMENT RELATIONS/REGULATIONS, LITIGATION, LINES OF BUSINESS/PRODUCTS, MARKETING STRATEGY/ACTIVITY, MARKET SHARE: COMPANY/BRAND, NEW PRODUCTS/SERVICES, ORDERS AND CONTRACTS, PROJECTIONS, RESEARCH AND DEVELOPMENT, SALES/EARNINGS, SALES BY PRODUCT/SALES BY PRODUCT LINE
Non-Billable Page Numbers:
1
Format:
PDF
Sections
Title
Starting Page
Number of Pages
Introduction
1
1
Introduction
2
1
About Healthcare
1
1
About Healthcare
2
1
Portfolio & Pipeline Analysis
1
2
Overview
9
1
Therapy Area Focus In 1999
2
2
Therapy Area Focus 1999
10
2
Business Development By Therapy Area
3
2
Table/Chart: Ethical Sales Derived From Main Therapy Areas 1998-99
10
1
Gastrointestinal Franchise
5
2
Business Development By Therapy Area
12
3
Gastrointestinal Franchise Marketed Products
6
1
Gastrointestinal Franchise
15
12
Losec/Prilosec (Omeprazole)
7
2
Table/Chart: Gastrointestinal Portfolio 1999
16
1
Substance Patents
9
1
Table/Chart: Marketed Gastrointestinal Products 1998-99
17
1
Formulation Patents
10
3
Table/Chart: Patent Expiry Dates For LOSEC
19
1
Gastrointestinal Franchise R&D Compounds
12
2
Table/Chart: Gastrointestinal R&D Pipeline 2005
24
1
Nexium (Esomeprazole)
13
2
Table/Chart: Forecast Sales Of Products In Gastrointestinal 1999-2005
26
1
Gastrointestinal Portfolio Sales & Revenue Growth
14
1
Cardiovascular Franchise
27
14
Cardiovascular Franchise
15
3
Table/Chart: Cardiovascular Portfolio 1999
28
2
Cardiovascular Franchise Marketed Products
18
1
Table/Chart: Marketed Cardiovascular Products 1998-99
30
1
Zestril & Zestoretic (Lisinopril + Chlorthalidone)
19
3
Table/Chart: Cardiovascular R&D Pipeline 2005
37
1
Seloken/Seloken ZOK (Metoprolol)
21
2
Table/Chart: Forecast Sales Of Products In Cardiovascular 1999-2005
40
1
Tenormin (Atenolol) & Tenoretic (Atenolol + Chlorthalidone)
22
1
CNS Franchise
41
11
Plendil (Felodipine)
23
1
Table/Chart: CNS Portfolio 1999
41
2
Atacand (Candesartan)
24
1
Table/Chart: Marketed CNS Products 1998-99
44
1
Cardiovascular Franchise R&D Compounds
24
2
Table/Chart: CNS R&D Pipeline 2005
48
1
ZD4522
25
2
Table/Chart: Forecast Sales Of Major Products In CNS Portfolio 1999-2005
51
1
Melagatran
26
1
Cancer Franchise
52
11
H376/95
26
1
Table/Chart: Cancer Portfolio 1999
53
1
Cardiovascular Portfolio Sales & Revenue Growth
26
2
Table/Chart: Marketed Cancer Products 1998-99
54
1
CNS Franchise
27
3
Table/Chart: Cancer R&D Pipeline 2005
60
1
CNS Franchise Marketed Products
30
1
Table/Chart: Forecast Sales Of Products In Cancer Portfolio 1999-2005
62
1
Diprivan (Propofol)
31
1
Respiratory Franchise
63
12
Xylocaine (Lidocaine)
31
1
Table/Chart: Respiratory Portfolio 1999
64
2
Seroquel (Quetiapine)
31
2
Table/Chart: Marketed Respiratory Products 1998-99
67
1
Zomig (Zolmitriptan)
32
2
Table/Chart: Respiratory R&D Pipeline 2005
72
1
CNS Franchise R&D Compounds
33
1
Table/Chart: Forecast Sales Of Major Products In Respiratory 1999-2005
74
1
Remacemide
34
1
Anti-Infectives Franchise
75
5
Zendra (Clomethiazole)
34
1
Table/Chart: Anti-Infectives Portfolio 1999
75
1
Other CNS Compounds
34
2
Table/Chart: Marketed Anti-Infectives Products 1998-99
76
1
CNS Portfolio Sales Forecasts & Forecast Revenue Growth
35
1
Table/Chart: Anti-Infectives R&D Pipeline 2005
78
1
Cancer Franchise
35
2
Table/Chart: Forecast Sales Of Products In Anti-Infectives 1999-2005
79
1
Cancer Franchise Marketed Products
36
2
Others Analysis
80
3
Zoladex (Goserelin)
37
2
Table/Chart: Non-Key Marketed Products 1998-99
80
1
Nolvadex (Tamoxifen)
38
1
Table/Chart: Prod. Outside Of Key Therapeutic Forecast Sales 1999-2005
82
1
Casodex (Bicalutamide)
38
2
Future Direction Of Therapeutic Strategy
83
3
Arimidex (Anastrozole)
39
2
Summary Product Sales 1999
86
1
Tomudex (Raltitrexed)
40
1
Table/Chart: Sales By Product 1998-99
86
3
Cancer Franchise R&D Compounds
40
3
Summary R&D Pipeline Of Astrazeneca 1999
89
1
Cancer Portfolio Sales Forecasts & Forecast Revenue Growth
42
1
Table/Chart: Research & Development Pipeline 1999
89
3
Respiratory Franchise
42
3
Respiratory Franchise Marketed Products
44
2
Pulmicort (Budesonide)
45
1
Oxis Turbuhaler (Formoterol)
45
2
Rhinocort (Budesonide)
46
1
Accolate (Zafirlukast)
46
2
Bricanyl (Terbutaline)
47
1
Bambec (Bambuterol)
47
1
Theo-Dur (Theophylline)
47
1
Mucomyst (Acetylcysteine)
47
1
Respiratory Franchise R&D Compounds
48
1
Symbicort (Formoterol+Budesonide)
48
1
Viozan
48
1
Rofleponide
49
1
Respiratory Portfolio Sales & Forecast Rev. Growth
49
1
Anti-Infectives Franchise
49
2
Anti-Infectives Franchise Marketed Products
50
2
Anti-Infectives Franchise R&D Compounds
51
1
Anti-Infective Compounds
51
1
Anti-Infective Portfolio Sales & Revenue Growth
51
1
Others
52
1
Others Marketed Products
52
1
MUSE (Alprostadil)
52
1
Other Product Sales Forecasts
52
1
Future Direction Of AstraZeneca's Therapeutic Strategy
53
1
Revenue Streams To 2005
53
2
Supporting Data
54
3
Summary R&D Pipeline Of Astrazeneca, 1999
56
2
TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.
Price: $3,600.00
Questions about
this research?
Send page to a friend
Return to
Alacra Company Snapshot
Get FREE Research
Sign up
here
to receive email alerts for FREE Research from Alacra Partners!
Can't Decide?
Purchasing premium research sight unseen can be intimidating. We want you to know what you are getting. Visit our
FAQ
or ask our
Customer Service Team
any questions about the report you are considering purchasing.
